Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Abeona Therapeutics (ABEO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart
Realtime quote and/or trade prices are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 755,497
  • Shares Outstanding, K 46,780
  • Annual Sales, $ 890 K
  • Annual Income, $ -21,870 K
  • 36-Month Beta 2.30
  • Price/Sales 849.74
  • Price/Cash Flow 0.00
  • Price/Book 8.27

Price Performance

See More
Period Period Low Period High Performance
1-Month
14.25 +18.95%
on 11/07/17
18.60 -8.87%
on 10/25/17
-0.90 (-5.04%)
since 10/24/17
3-Month
8.80 +92.61%
on 08/25/17
22.75 -25.49%
on 10/11/17
+7.35 (+76.56%)
since 08/24/17
52-Week
4.05 +318.52%
on 12/21/16
22.75 -25.49%
on 10/11/17
+9.95 (+142.14%)
since 11/23/16

Most Recent Stories

More News
Featured Company News - Celldex Starts Phase-2 Combination Study of CDX-3379 and Cetuximab in Head and Neck Squamous Cell Carcinoma

Research Desk Line-up: Abeona Therapeutics Post Earnings Coverage

CLDX : 2.94 (+1.73%)
ABEO : 16.90 (+4.64%)
LLY : 84.03 (+0.42%)
Abeona Reports Third Quarter 2017 Financial Results and Recent Business Highlights

-- Investor Conference Call to be held Monday, November 20th at 10:00 am ET

ABEO : 16.90 (+4.64%)
Abeona Enrolls First Subject in Spain in Ongoing Phase 1/2 Clinical Trial in MPS IIIA

- Company Opens European Subsidiary in Spain to Support Global Clinical Development

ABEO : 16.90 (+4.64%)
Abeona Enrolls First Subject in Spain in Ongoing Phase 1/2 Clinical Trial in MPS IIIA

-- Company Opens European Subsidiary in Spain to Support Global Clinical Development

ABEO : 16.90 (+4.64%)
Biotech Stocks on Investors' Radar -- Synthetic Biologics, 22nd Century, Abeona Therapeutics, and Aeterna Zentaris

If you want a Stock Review on SYN, XXII, ABEO, or AEZS then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. On Monday, October 30, 2017, US markets saw...

AEZS : 2.12 (+1.44%)
ABEO : 16.90 (+4.64%)
XXII : 2.43 (+2.97%)
SYN : 0.64 (-1.54%)
Abeona Announces Closing of $92 Million Underwritten Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene and cell therapies for life-threatening rare diseases, today announced the closing...

ABEO : 16.90 (+4.64%)
Positive Developments From Clinical Studies and FDA Approvals Pushing Biotech Stocks to New Highs

PALM BEACH, Florida, October 18, 2017 /PRNewswire/ --

ABEO : 16.90 (+4.64%)
APHB : 1.06 (+7.21%)
IONS : 54.94 (+1.10%)
ACAD : 28.17 (-0.28%)
XBI : 82.26 (+0.67%)
MBRX : 1.72 (-3.69%)
Positive Developments From Clinical Studies and FDA Approvals Pushing Biotech Stocks to New Highs

Biotech Briefing: The Biotech Sector continues to impress and even surprise many as the SPDR S&P Biotech ETF (XBI) has surged 49 percent in 2017 to its highest level in more than two years and some industry...

ABEO : 16.90 (+4.64%)
APHB : 1.06 (+7.21%)
IONS : 54.94 (+1.10%)
ACAD : 28.17 (-0.28%)
XBI : 82.26 (+0.67%)
MBRX : 1.72 (-3.69%)
Abeona Therapeutics (ABEO) Surges: Stock Moves 7.2% Higher

Abeona Therapeutics (ABEO) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

ABEO : 16.90 (+4.64%)
AXON : 5.55 (-1.77%)
Abeona Therapeutics Announces Pricing of Public Offering of Common Stock

Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene and cell therapies for life-threatening rare diseases, today announced the pricing...

ABEO : 16.90 (+4.64%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Abeona Therapeutics, Inc. is engaged in developing and delivering gene therapy and plasma-based products for rare diseases. Abeona Therapeutics Inc., formerly known as PlasmaTech Biopharmaceuticals, Inc., is based in Dallas, United States.

See More

Key Turning Points

2nd Resistance Point 16.65
1st Resistance Point 16.40
Last Price 16.90
1st Support Level 15.85
2nd Support Level 15.55

See More

52-Week High 22.75
Last Price 16.90
Fibonacci 61.8% 15.61
Fibonacci 50% 13.40
Fibonacci 38.2% 11.19
52-Week Low 4.05

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart